Peter Buhl | CEO
Peter Buhl Jensen has 35 years of experience in clinical cancer therapy and as a serial entrepreneur. He is the founder/co-founder of Oncology Venture A/S, TopoTarget A/S which he also led as the CEO. He has also co-founded and CHOSA ApS, and Buhl Oncology ApS and has been key in the development and approval of the cancer drugs Savene® (EU approval 2006, FDA 2007) & Belinostat® (FDA approval 2014). Buhl Jensen was the Chief Oncologist and chief executive at the Oncology department at Rigshospitalet (2000-08), and Aalborg University Hospital (2010-11).
Holdings in the Company: 15,506,935* shares, corresponding to approximately 24.7 percent of the shares in the Company.
Claus Frisenberg Pedersen | CFO
Claus Frisenberg Pedersen, born in 1972, has a master’s degree in strategy and organizational development from Copenhagen Business School and a Diploma (HD) in finance from Copenhagen Business School. Frisenberg Pedersen has long experience as a strategic advisor, with a primary focus on M&A, FMCG and Commercial Excellence. Frisenberg Pedersen also has management and founding experience from the biotechnology sector (Oncology Venture ApS; 2X Oncology Ltd.).Claus Frisenberg Pedersen’s other assignments include: Chairman of the Board of 2Ø ApS, Finn L & Davidsen A/S, Servicelovers ApS and SJEB A/S. Board member of Nel-lemann Holding A/S.
After the completion of the acquisition of Chosa, Claus Frisenberg Pedersen will indirectly hold 7,332,952 shares in the Company.
Ulla Hald Buhl | COO
Alexandra Ellervik | PR, Communication & IR